Patents Assigned to UNIVERSITÉ PARIS DESCARTES
-
Patent number: 10344279Abstract: The present invention relates to the prevention and the treatment of extracapillary glomerulonephritis such as rapidly progressive glomerulonephritis and collapsing glomerulonephritis.Type: GrantFiled: August 9, 2017Date of Patent: July 9, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MĖDICALE), UNIVERSITÉ PARIS DESCARTESInventors: Pierre-Louis Tharaux, Carole Henique-Greciet
-
Publication number: 20190201492Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.Type: ApplicationFiled: August 31, 2017Publication date: July 4, 2019Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Assistance Publique - Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Universite de Versailles-St Quentin en YvelinesInventors: Robert Malafosse, Nathalie Mignet, Vincent Boudy, Johanne Seguin, Kathia Lemdani, Claude Capron
-
Publication number: 20190192430Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.Type: ApplicationFiled: September 16, 2016Publication date: June 27, 2019Applicants: Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Assistance Publique-Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Nathalie Mignet, Vincent Pierre-Marie Boudy, Johanne Seguin, Daniel Scherman, Yoran Beldengrun
-
Patent number: 10329232Abstract: A calixarene directly grafted onto the surface of a material, a related grafting process, and certain calixarene intermediates useful for carrying out the grafting process.Type: GrantFiled: March 28, 2013Date of Patent: June 25, 2019Assignees: UNIVERSITE LIBRE DE BRUXELLES (ULB), CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE DE RENNES 1, UNIVERSITE PARIS DESCARTESInventors: Ivan Jabin, Alice Mattiuzzi, Corlnne Lagrost, Philippe Hapiot, Olivia Reinaud
-
Patent number: 10321771Abstract: Device for assisting crawling of an infant (2) on a training surface comprising: - a platform (1) comprising a chest supporting surface for supporting a chest of the infant (2) resting on the platform (1) in a prone position, and - rolling elements (9) rotatably mounted on the platform in such a way they can rotate 360 degrees (1) and arranged to be located between the platform (1) and the training surface, wherein the platform (1) is shaped so that, when the rolling elements (9) are in contact with the training surface, the chest supporting surface of the platform (1) is inclined relative to the training surface, so that the pelvis and the legs of the infant (2) are in contact with the training surface.Type: GrantFiled: July 16, 2015Date of Patent: June 18, 2019Assignees: Universite Paris Descartes, Centre National de la Recherche Scientifique (CNRS), Ecole Pratique Des Hautes Etudes, San Francisco State UniversityInventors: Marianne Barbu-Roth, Vincent Forma, Caroline Teulier, David Anderson, Joëlle Provasi, Benoist Schaal
-
Patent number: 10323078Abstract: A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.Type: GrantFiled: March 21, 2016Date of Patent: June 18, 2019Assignees: Universite Paris Descartes, Assistance Publique—Hopitaux De Paris, Universite Paris—Sud, Universite Pierre et Marie Curie (Paris 6), Institut National De La Sante et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Institut Gustave-RoussyInventors: Nicolas Dupin, Philippe Grange, Vincent Calvez, Joël Raingeaud
-
Patent number: 10317408Abstract: A method for assessment of a number or density of immune cells in tumoral tissues comprising the steps consisting in: a. providing one or more immunostained slices of tissue section obtained by an automated slide-staining system by using antibodies binding specifically to antigens (markers) expressed by immune cells. b. proceeding to digitalization of the slides of step a. by high resolution scan capture, whereby a high definition (4.6 ?m/pixel or better) digital picture of the slide to be analyzed is obtained, c. detecting the slice of tissue section on the digital picture d. analyzing the slice of tissue section for defining (i) the tumor (CT) and (ii) the invasive margin of the tumor (IM), e. providing a size reference grid with uniformly distributed units having a same surface, said grid being adapted to the size of the tumor to be analyzed, e1. checking the quality of immunostaining, f.Type: GrantFiled: June 14, 2013Date of Patent: June 11, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes, Assistance Publique-Hopitaux de ParisInventors: Jerome Galon, Franck Pages, Bernhard Mlecnik
-
Patent number: 10287298Abstract: The present invention concerns compounds of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diasteroisomers thereof formula (I): wherein at least one of W, X and Y is selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR3—(CH2)n—N?R6R7R8; and —O—(CH2)n—N?R6R7R8 and Z is a functional group capable of chelating iron salts. The present invention also concerns the compounds of formula (I) for use as a drug, in particular, in the treatment of cancer and malaria.Type: GrantFiled: September 14, 2015Date of Patent: May 14, 2019Assignees: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris DescartesInventors: Maryam Mehrpour, Raphael Rodriguez, Antje Hienzsch, Mai Trang, Ahmed Hamai
-
Publication number: 20190134110Abstract: The invention relates to a lyophilized composition comprising a microbiota in its ecosystem, in particular stools, and a mixture of cryoprotectant agents comprising maltodextrin and trehalose, a capsule comprising said lyophilized composition, the use thereof, and methods for the production thereof.Type: ApplicationFiled: December 16, 2016Publication date: May 9, 2019Applicants: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, UNIVERSITE PARIS DESCARTES, UNIVERSITE PARIS DIDEROT - PARIS 7, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Nathalie Kapel, Anne-Judith Waligora-Dupriet, Muriel Thomas, Christine Charrueau, Francisca Joly, Camille Mayeur, Véronique Robert, Johanne Delannoy
-
Publication number: 20190125723Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvirinae, in particular to the human herpesvirus 8 (HHV8) or the human herpes virus 4 (HHV4), and pharmaceutical compositions containing such compounds.Type: ApplicationFiled: June 28, 2017Publication date: May 2, 2019Applicants: Assistance Publique - Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Pierre et Marie Curie (Paris 6), Universite Paris Descartes, Centre National de la Recherche Scientifique (CNRS)Inventors: Nicolas Dupin, Anne-Geneviève Marcelin, Vincent Calvez, Philippe Grange
-
Publication number: 20190099264Abstract: The present invention relates to an electrospun fully biodegradable vascular valved prosthesis, allowing tissue regeneration and growth potential optionally comprising a bifurcation, preferably T-shaped, a mandrel for electrospinning said vascular valved prosthesis, and a method for electrospinning said vascular valved prosthesis.Type: ApplicationFiled: March 21, 2017Publication date: April 4, 2019Applicants: Assistance Publique-Hôpitaux de Paris, Statice, Universite Paris DescartesInventors: David Kalfa, Philippe Menasché, Pierre Pouponneau, Clément Leonard, Sébastien Perrot
-
Publication number: 20190101549Abstract: The present invention relates to a novel use of total cellular iron, preferably under the form of ferrous iron (Fe2+), as a marker of cancer stem cells (CSCs). The invention also relates to methods using said iron marker, in particular for metastatic cancer diagnosis or treatment, for screening for compounds of interest, as well as for killing CSCs.Type: ApplicationFiled: March 8, 2017Publication date: April 4, 2019Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Paris DescartesInventors: Maryam Mehrpour, Raphael Rodriguez, Ahmed Hamai, Mai Trang
-
Patent number: 10247722Abstract: Today, despite current advances in combinatorial therapies such as surgery, radiotherapy and chemotherapy, aggressive cancers remain fatal. Cancer stem-like cells (CSCs) may account for chemotherapy resistance and thus represent a promising therapeutic target. In this context, the present inventors identified essential intracellular pathways favoring the self-renewal and survival of CSCs. More precisely, the present inventors showed that the cytokine co-receptor GP130 acts as a co-receptor for Apelin/APJ signaling and that the interaction of Apelin with APJ/GP130 activates a dual signaling pathway involving the Akt/mTOR and STAT3 transcription factor, thereby promoting CSCs survival and self-renewal. They therefore propose to block these pathways in order to treat patients suffering from tumors containing CSCs, such as glioblastomas. In another aspect, the invention relates to the use of the Apelin expression level for evaluating the survival probability of a subject suffering from glioblastoma.Type: GrantFiled: March 20, 2015Date of Patent: April 2, 2019Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Julie Gavard, Eva-Maria Galan-Moya
-
Publication number: 20190031639Abstract: The present invention relates to compounds of the following general formula (I) or (II): or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment and/or in the prevention of ErbB2 dependent cancers, and pharmaceutical compositions containing such compounds.Type: ApplicationFiled: January 11, 2017Publication date: January 31, 2019Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris DescartesInventors: Sandrine Bourdoulous, Camille Faure
-
Patent number: 10191059Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.Type: GrantFiled: May 20, 2015Date of Patent: January 29, 2019Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris DescartesInventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
-
Patent number: 10174106Abstract: The present invention relates to a neutralizing antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralizes the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralizing antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.Type: GrantFiled: June 1, 2015Date of Patent: January 8, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris DescartesInventor: Patricia Forgez
-
Patent number: 10167468Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.Type: GrantFiled: January 31, 2017Date of Patent: January 1, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LORRAINE, CENTRE HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU), UNIVERSITE PARIS DIDEROT-PARIS 7, UNIVERSITE PARIS DESCARTESInventors: Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
-
Patent number: 10159684Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.Type: GrantFiled: June 8, 2017Date of Patent: December 25, 2018Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP)Inventors: Nicolette Farman, Frederic Jaisser, Francine Behar-Cohen, Selin Aractingi, Van Tuan Nguyen
-
Patent number: 10159227Abstract: The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.Type: GrantFiled: November 5, 2014Date of Patent: December 25, 2018Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Paris—Sud, Commissariat a l'Energie Atomique et aux Energies Alternatives, Centre National de la Recherche Scientifique (CNRS), Universite Paris DescartesInventors: Nathalie Cartier-Lacave, Jerome Braudeau, Nicole Deglon, Philippe Hantraye, Mickael Audrain
-
Patent number: 10151745Abstract: The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(?) iNKT cell sub-population. In particular, CD3+CD4? TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.Type: GrantFiled: November 21, 2013Date of Patent: December 11, 2018Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Assistance Publique—Hopitaux de Paris, Universite Paris Descartes, Imagine Institut des Maladies Genetiques Necker Enfants MaladesInventors: Olivier Hermine, Marie Thérèse Rubio, Marie Bouillie, Maria Leite de Maraes